Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference

   Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual
                            Healthcare Conference

PR Newswire

CHESTERBROOK, Pa., Jan. 8, 2014

CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ --Auxilium Pharmaceuticals, Inc.
(NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today
announced that the executive management team will participate in the J.P.
Morgan 32^nd Annual Healthcare Conference to be held January 13-16, 2014 at
the Westin St. Francis Hotel in San Francisco. Adrian Adams, Chief Executive
Officer and President, is scheduled to present an overview of the Company and
its product portfolio at 4 p.m. PT on Wednesday, January 15, 2014.

(Logo:http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

"The past year has been a transformational one for Auxilium as we expanded our
portfolio from two products to 12 and secured a strong anchor position in the
men's healthcare area," said Mr. Adams. "We look forward to discussing our
strategy for continued growth in 2014, including the launch of two new
products – STENDRA™ (avanafil) an oral treatment for erectile dysfunction and
XIAFLEX® (collagenase clostridium histolyticum or CCH), the first and only
proven safe and effective FDA-approved non-surgical treatment option for
Peyronie's disease in men with a palpable plaque and a curvature deformity of
30 degrees or greater at the start of therapy – this month."

The presentation slides to be used during the call will be available in the
"Investors" section of the Auxilium web site under the "Presentations" tab on
January 13, 2014. The presentation and the presentation slides will be
simultaneously web cast on the "Investors" section of the Auxilium web site
under the "Events" tab on January 15, 2014. A question and answer session will
follow the presentation and will be webcast. To access the live webcast,
please log on to Auxilium's site approximately 15 minutes prior to the
presentation to register and download any necessary audio software. The
presentation replay will be available for 90 days after the event.

About STENDRA
STENDRA (avanafil) is approved by the FDA for the treatment of erectile
dysfunction in the U.S. Auxilium sublicensed this product from VIVUS, Inc. in
late 2013 and is in the very early stages of commercializing STENDRA in the
U.S. VIVUS licensed avanafil from Mitsubishi Tanabe Pharma Corporation (MTPC).

STENDRA will be available through retail and mail order pharmacies. The
Company plans to offer programs that will help with patients' out-of-pocket
costs.

STENDRA is rapidly absorbed and can be taken 30 minutes before sexual activity
on an as-needed basis. STENDRA should not be taken more than once per day and
can be taken without regard to food and has modest alcohol consumption
requirements. For more information about STENDRA, please visit
www.stendra.com.

About XIAFLEX
XIAFLEX (collagenase clostridium histolyticum, or CCH) is a biologic approved
in the U.S., EU, Canada and Australia for the treatment of adult Dupuytren's
contracture (DC) patients with a palpable cord and for the treatment of adult
men with Peyronie's disease (PD) with a palpable plaque and curvature
deformity of at least 30 degrees at the start of therapy in the U.S. XIAFLEX
consists of a combination of two subtypes of collagenase, derived from
Clostridium histolyticum. Together, the collagenase sub-types are thought to
work synergistically to break the bonds of the triple helix collagen
structure. XIAFLEX has been granted Orphan status in the U.S. by the FDA for
DC and PD.

About Auxilium
Auxilium Pharmaceuticals, Inc. is a fully integrated specialty
biopharmaceutical company with a focus on developing and commercializing
innovative products for specialist audiences. With a broad range of first- and
second-line products across multiple indications, Auxilium is an emerging
leader in the men's healthcare area and has strategically expanded its product
portfolio and pipeline in orthopedics, dermatology and other therapeutic
areas. The Company now has a broad portfolio of 12 approved products. In the
U.S., Auxilium markets Edex® (alprostadil for injection), an injectable
treatment for erectile dysfunction, Osbon ErecAid®, the leading device for
aiding erectile dysfunction, STENDRA™ (avanafil), an oral erectile dysfunction
therapy, Testim® (testosterone gel) for the topical treatment of hypogonadism,
TESTOPEL® (testosterone pellets) a long-acting implantable testosterone
replacement therapy, XIAFLEX® (collagenase clostridium histolyticum or CCH)
for the treatment of Peyronie's disease and XIAFLEX for the treatment of
Dupuytren's contracture. The Company also has programs in Phase 2 clinical
development for the treatment of Frozen Shoulder syndrome and cellulite.
Auxilium's mission is to improve the lives of patients throughout the world by
successfully identifying, developing and commercializing innovative specialty
biopharmaceutical products. To learn more, please visit www.Auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995
This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, including statements made
with respect to: the Company's intention to participate in the J.P. Morgan
32^nd Annual Healthcare Conference; the timing and success of Auxilium's
launches of XIALFLEX for the treatment of Peyronie's disease and of STENDRA;
Auxilium's other product candidates; and other statements regarding matters
that are not historical facts, and involve predictions. These statements
involve known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or prospects
expressed in or implied by such forward-looking statements. In some cases you
can identify forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'',
''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of
these terms or similar expressions, although not all forward-looking
statements contain these identifying words. Although forward-looking
statements are based on Auxilium's current plans or assessments that are
believed to be reasonable as of the date of this press release, they
inherently involve certain risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties, including those
discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for
the year ended December 31, 2012 and in other public filings with the SEC,
including, without limitation, as such Form 10-K was updated in Item 8.01 of
the Current Report on Form 8-K filed on April 29, 2013 and Auxilium's
Quarterly Reports for 2013. While Auxilium may elect to update the
forward-looking statements made in this news release in the future, Auxilium
specifically disclaims any obligation to do so. Auxilium's SEC filings may be
accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov. There may be additional risks that Auxilium does not
presently know or that Auxilium currently believes are immaterial which could
also cause actual results to differ from those contained in the
forward-looking statements.

Auxilium Contacts:
Keri P. Mattox / SVP, IR &     Nichol L. Ochsner / Senior Director, IR &
Corporate Communications       Corporate Communications
Auxilium Pharmaceuticals, Inc. Auxilium Pharmaceuticals, Inc.
(484) 321-5900                 (484) 321-5900
kmattox@auxilium.com           nochsner@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com
 
Press spacebar to pause and continue. Press esc to stop.